Pharma major Sun Pharmaceutical Industries said its short-term outlook continues to be challenging and expects a single-digit decline in consolidated revenues for FY18.
"The short-term outlook continues to be challenging as the US generics industry is facing rapidly changing market dynamics.
"In the Indian market, there is uncertainty amongst the trade channels due to the GST implementation, although it may be temporary. Given these factors, growth could be a challenge in FY18 and we expect a single-digit decline in consolidated revenues for FY18 over FY17," Shanghvi said.
The company's consolidated R&D investments for FY18 will be about 9-10 per cent of revenues.
"Our R&D investment in FY17 was Rs 23 billion, targeted mainly at developing complex generics and specialty products. R&D is the engine, which will drive our journey of moving up the pharmaceutical value chain.
"We are also investing in enhancing our product pipeline for emerging markets and other non-US developed markets. We continued to build our specialty pipeline during the year and simultaneously investing in developing the requisite front-end for this business in the US. We expect this trend to continue in future as well," the managing director said.
The company is entering into the third and the most important year of integration of Ranbaxy with the company.
To Get More Share Market Updates Visit - http://asianresearchhouse.com/ or Miss call @8085999888
No comments:
Post a Comment